Antiangiogenic therapy in neovascular age-related macular degeneration

International Ophthalmology Clinics

Volumn 47, Issue 1, 2007, Pages 117-137

  Lin, Richard C ^a   Rosenfeld, Philip J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; ANGIOSTATIC STEROID; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; CORTICOSTEROID; PEGAPTANIB; RANIBIZUMAB; STEROID; TRASTUZUMAB; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CATARACT; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG DOSE ESCALATION; ENDOPHTHALMITIS; EYE DISEASE; GLAUCOMA; HEART INFARCTION; HUMAN; INTRAOCULAR PRESSURE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRITIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846422412     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e31802bd873     Document Type: Review

References (63)

1. Seddon JM, Chen CA. Epidemiology of age-related macular degeneration. In: Ryan SJ, ed. The Retina. 4 ed. Philadelphia: Elsevier; 2006:1017-1114.
2. Campochiaro PA. Ocular neovascularisation and excessive vascular permeability. Expert Opin Biol Ther. 2004;4:1395-1402.
3. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111-118.
4. Ferrera N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611.
5. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites. Science. 1983;219:983-985.
6. Leung DW, Cachianes G, Kuang W, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
7. Keck PJ, Hauser WJ, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309-1312.
8. Levy AP, Levy NS, Wegner S, et al. Transcriptional regulation of the rat endothelial growth factor gene by hypoxia. J Biol Chem. 1995;270:13333-13340.
9. de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255:989-991.
10. Terman BI, Dougher Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992;187:1579-1586.
11. Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific VEGF mutants. J Biol Chem. 2001;276:3222-3230.
12. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Opthalmol. 1994;118:445-450.
13. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
14. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Opthalmol. 2004;122:1801-1807.
15. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
16. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71.
17. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
18. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Opthalmol. 2002;120:338-346.
19. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;120:338-346.
20. Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996;114:964-970.
21. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
22. Lopez PF, Sippy BD, Lambert M, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
23. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvas Res. 2002;64:162-169.
24. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol. 1999;117:1329-1345.
25. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25:119-134.
26. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP report no.2. Arch Ophthalmol. 2003;121:1253-1268.
27. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123:448-457.
28. QLT Announces Two Year Results of Visudyne® in Occult (VIO) Trial. September 20, 2005. Available at: http://www.qltinc.com/Qltinc/pages/ pagespressdetail.cfm?PressID= 252&InternetPageID=31&YearRange= 2005&Type=Current&Criteria=VIO&cr =5. Accessed June 5, 2006.
29. Butler JM, Guthrie SM, Koc M, et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest. 2005;115:86-93.
30. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005;80:249-258.
31. Penfold PL, Wen L, Madigan MC, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol. 2000;121:458.
32. Spaide RF, Soronson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301-304.
33. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;141:638-645.
34. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985;230:1375-1378.
35. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology. 2003;110:2372-2385.
36. Slakter JS, Bochow T, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology. 2006;113:3-13.
37. 165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem. 1998;273:20556-20567.
38. The Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of neovascular age-related macular degeneration. Retina. 2002;22:143-152.
39. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2003;110:979-986.
40. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. New Engl J Med. 2004;351:2805-2816.
41. Ferrara N, Hillan KJ, Gerber H, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
42. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335.
43. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
44. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
45. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
46. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
47. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
48. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511.
49. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536-544.
50. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-269.
51. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293:865-881.
52. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-1053.
53. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:623-632.
54. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2006;113:633-642.
55. Preliminary data from phase III trial show Lucentis is the first investigational therapy to demonstrate clinical benefit over visudyne in a head-to-head study of patients with wet AMD. November 7, 2005. Available at: http://www.gene.com/gene/news/ press-releases/display.do?method=detail&id= 9087&categoryid=4. Accessed June 22, 2006.
56. Genentech granted six-month priority review for Lucentis for the treatment of wet age-related macular degeneration. February 28, 2006. Available at: http://www.gene. com/gene/news/press-releases/display.do?method= detail&id=9427&categoryid=4. Accessed June 22, 2006.
57. Preliminary phase III data from head-to-head study of Lucentis shows Lucentis improved vision compared to visudyne in patients with wet age-related macular degeneration. January 14, 2006. Available at: http://www.gene.com/gene/ news/ press-releases/display.do?method=detail&id=9037. Accessed June 22, 2006.
58. Preliminary results from a phase IIIb study showed patients with wet AMD treated with Lucentis quarterly experienced a 16-letter benefit over the control group at one year. June 2, 2006. Available at: http://www.gene.com/gene/news/ press-releases/ display.do?method=detail&id=9747. Accessed June 22, 2006.
59. Lalwani G, Fung AE, Michels S, et al. Optical coherence tomography findings in a variable-dosing regimen with ranibizumab (Lucentis™): the PrONTO study. Presented at the 2006 Association for Research in Vision and Ophthalmology Meeting.
60. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP (R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of blood-retinal barrier. J Cell Physiol. 2003;195:241-248.
61. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis. 2003;9:210-216.
62. Acuity Pharmaceuticals reports positive initial phase II results for bevasiranib (CAND5) in wet AMD. June 1, 2006. Available at: http://www. acuitypharma.com/press/release13.pdf. Accessed June 22, 2006.
63. Sirna Therapeutics, Therapeutic Pipeline: ocular. 2006. Available at: http://www.sirna.com/wt/page/ocular. Accessed June 28, 2006.